Immunotherapy HPV Protein Used in Cervical Cancer Shows Low Response Rate But Overall Improvement of Over 50%
Don Dizon, MD of Massachusetts General Hospital discusses the use of immunotherapy in cervical cancer treatment. He explains a clinical trial where an HPV protein was used for treatment and although there was a low response rate, there was overall improvement of over 50%. This was recorded at the 2017 Society of Gynecologic Oncology (SGO)’s Annual Meeting on Women’s Cancer® in National Harbor, MD.
Immunotherapy HPV Protein Used in Cervical Cancer Shows Low Response Rate But Overall Improvement of Over 50%
Source: Virology News
